摘要:
The present invention relates to new 2-amino-5-cyano-4-quinolyl-l, 4-dihydropyridine esters of the general formula (I) ##STR1## in which R.sub.1 to R.sub.3 have the meaning given in the description, to processes for their preparation and to their use in medicaments, especially in agents for the treatment of cardiac circulatory disorders.
摘要:
The present invention relates to new 2-amino-4-quinolyl-1,4-dihydropyridines of the general formula (I) ##STR1## in which R.sub.1 -R.sub.4 have the meaning given in the description, to processes for their preparation and to their use in medicaments, especially in agents for the treatment of cardiac circulatory disorders.
摘要:
The present invention relates to new 2-amino-4-heteroaryl-1,4-dihydropyridines of the general formula (I) ##STR1## in which R.sub.1 to R.sub.4 have the meaning given in the description, processes for their preparation and their use in medicaments, in particular in compositions for the treatment of cardiovascular disorders.
摘要:
The present invention relates to the use of 3-formyl-1,4-dihydropyridine derivatives as medicaments for the control of cardiovascular diseases, in particular of pathologically changed blood pressure and of cardiac insufficiency, new compounds and a process for their preparation.
摘要:
Circulation-active dihydropyridines of the formula ##STR1## in which R.sup.1 is H, CN, NO.sub.2 or --COOR.sup.7,R.sup.7 is H, alkyl or various other radicals,R.sup.2 and R.sup.4 each independently is alkyl or other radicals,R.sup.3 is H or optionally substituted alkyl, andR.sup.5 completes a keto or ester group,and physiologically acceptable salts thereof. Also the aldehyde intermediate therefor of the formula ##STR2##
摘要:
The present invention relates to new 2-amino-5-cyano-4-quinoline-1,4-dihydropyridines, processes for their preparation and their use in medicaments, in particular in agents for the treatment of cardiovascular diseases.
摘要:
Positive inotropically active 4-quinolyl-dihydropyridines of the formula ##STR1## in which R.sup.1 and R.sup.5 are identical or different and represent straight-chain or branched alkyl having up to 8 carbon atoms,R.sup.2 represents nitro or cyano, orR.sup.1 and R.sup.2 together form a lactone ring of the formula ##STR2## R.sup.3 represents a radical of the formula ##STR3## in which R.sup.6 - denotes hydrogen, halogen or straight-chain or branched alkyl or alkoxy in each case having up to 8 carbon atoms,R.sup.7 denotes aryl, thienyl or pyridyl, andR.sup.4 represents hydrogen, or optionally substituted alkyl, alkenyl, alkadienyl or alkynyl,and their physiologically acceptable salts.
摘要:
Cardioactive novel dihydropyridine ethers of the formula ##STR1## in which R.sup.1 -stands for cyano, nitro or for a -COOR.sup.5 group,whereinR.sup.5 -denotes straight-chain, branched or cyclic alkyl having up to 6 carbon atoms, which can be interrupted by an oxygen in the chain and which can be monosubstituted or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxyl, phenyl, phenoxy or by a group of the formula ##STR2## R.sup.2 -stands for aryl having 6 to 12 carbon atoms, which can be monosubstituted, disubstituted or trisubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, alkyl having up to 4 carbon atoms or alkoxy having up to 4 carbon atoms,R.sup.3 -stands for aryl having 6 to 12 carbon atoms, or stands for straight-chain, branched or cyclic alkyl having up to 6 carbon atoms andR.sup.4 -stands for straight-chain alkyl having up to 4 carbon atoms or for amino or a physiologically acceptable salt thereof.
摘要:
1,4-Dihydropyridine-3-carboxylic acid piperazides of the formula ##STR1## in which R.sup.1 is CN or alkyl, preferably methyl,R.sup.2 is H, CN, NO.sub.2 or preferably carboxyalkyl,R.sup.3 is aryl or heterocyclic, andR.sup.4 is alkyl, cycloalkyl, aryl or an acyl radical,and physiologically acceptable salts thereof, are circulation active. Novel intermediates are also provided.
摘要:
In a process for the quantitative optical analysis of fluorescently labelled biological cells 5, a cell layer on a transparent support at the bottom 2 of a reaction vessel 1 is in contact with a solution 3 containing the fluorescent dye 4. The sensitivity of analytical detection can be considerably improved if to the fluorescent dye 4 already present in addition a masking dye 9, which absorbs the excitation light 6 for the fluorescent dye 4 and/or its emission light 7, is added to the solution 3 and/or if a separating layer 10 permeable to the solution and absorbing and/or reflecting the excitation light 6 or the emission light 7 is applied to the cell layer at the bottom 2. This process can also be used for improving the sensitivity in the quantitative optical analysis of a luminescent biological cell layer. The separating layer 10 must in this case be composed such that it has a high power of reflection for the luminescent light 11. Analogously, these process principles can also be used in receptor studies for the masking of the interfering background radiation in the quantitative optical analysis of fluorescently or luminescently labelled reaction components. In this case, a receptor layer 12 at the bottom 2 of a reaction vessel 1 is in contact with a solution (supernatant 3) in which a fluorescent or luminescent ligand 13 is dissolved. The sensitivity and accuracy of the analytical detection can be considerably improved here if a masking dye 9 which absorbs the excitation light 6 for the fluorescent dye and/or its emission light or (in the case of luminescent ligands) the luminescent light is added to the supernatant 3. Instead of the masking dye in the solution 3 or optionally as an additional measure, a separating layer 10 permeable to the solution 3 and absorbing and/or reflecting the excitation light 6 and/or the emission light or the luminescent light can be applied to the cell or receptor layer 12 at the bottom 2.